Table 3 Factors associated with survival by multivariate analysis.

From: Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma

Factor

Hazard ratio (95% CI)

p

Overall survival

Short DTI (0–22 days)

2.03 (1.18–3.52)

0.011

Nonuse of rituximab

2.88 (1.39–5.96)

0.005

IPI score

1.25 (1.001–1.55)

0.049

Progression free survival

Short DTI (0–22 days)

2.08 (1.31–3.33)

< 0.001

Nonuse of rituximab

3.68 (1.67–8.09)

0.001

IPI score

1.45 (1.22–1.72)

0.002

  1. DTI diagnosis-to-treatment interval, IPI International Prognostic Index.
Back to article page